1. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
- Author
-
Li, Wang, Markus H, Kainulainen, Nannan, Jiang, Han, Di, Gaston, Bonenfant, Lisa, Mills, Michael, Currier, Punya, Shrivastava-Ranjan, Brenda M, Calderon, Mili, Sheth, Brian R, Mann, Jaber, Hossain, Xudong, Lin, Sandra, Lester, Elizabeth A, Pusch, Joyce, Jones, Dan, Cui, Payel, Chatterjee, M Harley, Jenks, Esther K, Morantz, Gloria P, Larson, Masato, Hatta, Jennifer L, Harcourt, Azaibi, Tamin, Yan, Li, Ying, Tao, Kun, Zhao, Kristine, Lacek, Ashley, Burroughs, Wei, Wang, Malania, Wilson, Terianne, Wong, So Hee, Park, Suxiang, Tong, John R, Barnes, Mark W, Tenforde, Wesley H, Self, Nathan I, Shapiro, Matthew C, Exline, D Clark, Files, Kevin W, Gibbs, David N, Hager, Manish, Patel, Alison L, Halpin, Laura K, McMullan, Justin S, Lee, Hongjie, Xia, Xuping, Xie, Pei-Yong, Shi, C Todd, Davis, Christina F, Spiropoulou, Natalie J, Thornburg, M Steven, Oberste, Vivien G, Dugan, David E, Wentworth, and Xiao-Yu, Zheng
- Subjects
Vaccines, Synthetic ,COVID-19 Vaccines ,Multidisciplinary ,SARS-CoV-2 ,COVID-19 ,General Physics and Astronomy ,General Chemistry ,Antibodies, Viral ,Antibodies, Neutralizing ,General Biochemistry, Genetics and Molecular Biology ,Neutralization Tests ,Spike Glycoprotein, Coronavirus ,Humans ,mRNA Vaccines ,Pandemics - Abstract
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccine-mediated protection from disease. To ascertain and rank the risk of VOCs and VOIs, we analyze the ability of 14 variants (614G, Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu, and Omicron) to escape from mRNA vaccine-induced antibodies. The variants show differential reductions in neutralization and replication by post-vaccination sera. Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic.
- Published
- 2022